SOURCE: Elsevier


August 03, 2009 09:15 ET

Global Medtech Companies and Medtech VCs Will Disclose Investment Preferences at Elsevier's 'Medical Device Investor Day' in San Francisco October 19th

Event Precedes 'IN3 Summit', the Largest Annual Strategic Partnership and Investment Meeting

SAN FRANCISCO, CA--(Marketwire - August 3, 2009) - Elsevier Business Intelligence, the medtech industry's leading strategic partner and investment conference organizer, announced today that it will host 'Medical Device Investor Day' on October 19th at San Francisco's InterContinental Mark Hopkins Hotel. This event is the prelude to 'IN3 Summit', also being held at the InterContinental Mark Hopkins, on October 20-21.

Medical Device Investor Day is a unique event for medical technology executives who are interested in what the leaders of the industry are thinking, doing, and planning in terms of investment. Senior execs from large medtech multinationals such as Medtronic and Becton Dickinson, along with managing directors from leading VC firms with a device focus such as Ascension Health Ventures, MedVenture Associates, New Leaf Venture Partners, Saints Capital and Versant Ventures, will speak candidly about what interests them most in the medtech space today.

"There are investors who are doing early-stage rounds," said Jeani Delagardelle, Managing Director, New Leaf Venture Partners. "I've talked to some of my colleagues at other firms and they're saying, 'We're going to stick to our strategy even though there are a lot more risks today, but we still think that we can get some good value if we invest early.' However, entrepreneurs seeking Series A funding today, unlike in the past, should try to accomplish more on the seed round such as to get to proof of concept with an animal model or even a human model outside of the U.S. -- and then go and raise their Series A.

"As far as later-stage companies looking for money in this environment, there are many compelling opportunities at great valuations that have been de-risked," added Delagardelle. "So it makes sense for us to take a look at these opportunities first. There are several opportunities to provide the last round to profitability or growth capital to companies with strong fundamentals," added Delagardelle, who will participate as a panelist during Medical Device Investor Day on October 19th.

Medical Device Investor Day will be followed by IN3 Summit on October 20-21 at the InterContinental Mark Hopkins Hotel. IN3 Summit is the largest annual strategic partnership and investment meeting for senior-level medical technology executives. Hundreds of venture capital firms and medical technology companies are expected to attend IN3 Summit on October 20th and 21st to hear about the latest innovations and investment opportunities from more than 50 emerging medical technology companies seeking funding and/or strategic partnerships.

For more information about Medical Device Investor Day and IN3 Summit, visit or contact Kristy Grimes at 480-985-9512, 888-290-2225 (U.S. toll-free), or email

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as Science Direct (, MDConsult (, Nursing Consult (, Scopus (, bibliographic databases, and online reference works.

Elsevier ( is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (, a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Contact Information

  • Contact:
    Ronald Trahan, APR
    Ronald Trahan Associates Inc.
    508-359-4005, x108